Showing results (31-40 of 51) with videos related to

Sort By:
Pageof 6
Acta Oncologica (Stockholm, Sweden)|April 25, 2007
Amplification of TOP2A and HER-2 genes in breast cancers occurring in patients harbouring BRCA1 germline mutationsAnne I Hagen, Anna M Bofin, Borgny Ytterhus, et al.
The British Journal of Surgery|February 12, 2011
Risk of recurrence following delayed large flap reconstruction after mastectomy for breast cancerA E Isern, J Manjer, J Malina, et al.
Neurobiology of Disease|November 5, 2013
Exacerbation of ischemic brain injury in hypercholesterolemic mice is associated with pronounced changes in peripheral and cerebral immune responsesJosephine Herz, Sabine I Hagen, Eileen Bergmüller, et al.
Breast (Edinburgh, Scotland)|February 24, 2007
Sensitivity of MRI versus conventional screening in the diagnosis of BRCA-associated breast cancer in a national prospective seriesAnne I Hagen, Kjell Arne Kvistad, Lovise Maehle, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 26, 2001
Development and homeostasis of T cell memory in rhesus macaqueChristine J Pitcher, Shoko I Hagen, Joshua M Walker, et al.
Breast Cancer Research and Treatment|August 1, 2013
Molecular subtypes, histopathological grade and survival in a historic cohort of breast cancer patientsM J Engstrøm, S Opdahl, A I Hagen, et al.
Clinical and Experimental Immunology|November 11, 2014
The wingless-related integration site-5a/secreted frizzled-related protein-5 system is dysregulated in human sepsisD M Schulte, D Kragelund, N Müller, et al.
Journal of Virology|June 22, 2012
Glycosylation of simian immunodeficiency virus influences immune-tissue targeting during primary infection, leading to immunodeficiency or viral controlChie Sugimoto, Shinichiro Nakamura, Shoko I Hagen, et al.
Hereditary Cancer in Clinical Practice|April 19, 2016
Intensive breast screening in BRCA2 mutation carriers is associated with reduced breast cancer specific and all cause mortalityD G Evans, E F Harkness, A Howell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 29, 2005
Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancerPer E Lønning, Jürgen Geisler, Lars E Krag, et al.
Pageof 6